Ukko Overview
Ukko's mission is to improve the lives of people with food allergies and sensitivities. Ukko uses immunology, machine learning, and protein engineering to make measurably better and safer proteins for use in food and therapeutics. Ukko does this by designing and controlling the molecular interactions between allergen proteins and the immune system. Ukko's technology uses samples from patients and machine learning to guide the engineering of superior proteins that can be incorporated into food products and therapeutics. These proteins maintain or improve beneficial properties (taste, nutritional value, yield, and physicochemical and mechanical properties) but do not trigger an immune response. Ukko's initial product pipeline includes celiac-safe gluten proteins, allergy-safe and therapeutic peanut proteins, as well as a pipeline of additional allergen proteins.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
"פיתחנו גלוטן בטוח עבור חולי צליאק שמספרם מכפיל את עצמו כל כמה שנים" כלכליסט
Ukko, an American-Israeli company, has developed safe gluten and proteins for individuals with food allergies. The company uses genetic engineering to produce safe proteins that retain their beneficial properties while eliminating the harmful ones. Ukko focuses on addressing gluten sensitivity, a condition that affects individuals with celiac disease. The company has also developed medications for other food allergies, such as nut allergies. Ukko has raised $48 million in funding and is supported by various companies, including Baer. The goal of Ukko is to create a healthier and safer world for everyone.
Customers
growth-positive
The Israeli startup trying to reimagine wheat
Ukko, an Israeli startup, is using artificial intelligence to redesign gluten and peanut proteins to help those with celiac disease and peanut allergies. The company has engineered a gluten protein that does not contain the component that triggers an immune response in celiac patients. In addition, Ukko is working on modifying peanut proteins to neutralize their ability to trigger allergic reactions. The company has raised $40 million in a funding round led by Bayer and Khosla Ventures. The funds will be used to move from initial development to clinical trials within the next two years.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins for food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko also plans to conduct clinical trials in Israel for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko raises $40 million to develop solutions for food allergies and sensitivities
Israeli biotechnology startup Ukko has completed a $40 million series B funding round led by Leaps by Bayer. The company uses patient data, machine learning, and AI to engineer food proteins that can be incorporated into food products, plants, and therapeutics. The funding will be used to expand Ukkos teams in the U.S. and Israel and accelerate the development of unique food proteins, with a focus on peanut and gluten-related disorders. Ukko plans to manufacture bread and pastries that are safe for people with Celiac disease and conduct clinical trials for medicine to fight against allergies. The company was founded in 2016 by Anat Binur and Yanay Ofran.
InvestmentExpand
growth-positive
Ukko scores $40m in Bayer-led Series B for anti-allergy foodtech
Israeli biotech startup Ukko has raised $40 million in a Series B round led by Bayers corporate venture unit, Leaps by Bayer. The funding will be used to develop functional food ingredients and therapeutics to eliminate food allergies and sensitivities, with an initial focus on gluten and peanut allergies. Ukkos approach combines artificial intelligence and bio-engineering to alter food proteins in a way that eliminates their ability to trigger allergies while maintaining their nutritional characteristics. The company aims to enter clinical trials for its investigational therapeutic for peanut allergy. The funding round included participation from several investors, including Continental Grain Company, PeakBridge Ventures, Skyviews Life Science, and Fall Line Capital.
Investment
| Sector | Agriculture & Food Technologies |
Funding
| Total funding | $47.7M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 3 |
| Investors | 11 |
Team Members
5
Employees: 51-200
Web & Social Links
| Website | www.ukko.us/ |
Locations
HaMada Street 12, Rehovot, Israel
1845 El Camino Real, Palo Alto, CA 94306, USA
Photos & Videos
No files yet
